0 Comments
0 Shares
234 Views
0 Reviews
Search
Discover new people, create new connections and make new friends
-
Please log in to like, share and comment!
-
What’s Next in the Duchenne Muscular Dystrophy Market After Exon-Skipping Therapies?What’s Next in the Duchenne Muscular Dystrophy Market After Exon-Skipping Therapies? Duchenne Muscular Dystrophy Market: What’s More Beyond Exon-Skipping Therapies? Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, and the lack of dystrophin, a protein crucial for muscle function,...0 Comments 0 Shares 503 Views 0 Reviews
-
A New Era in Duchenne Muscular Dystrophy: Inside Sarepta’s ELEVIDYS TherapySarepta Therapeutics has ushered in a new chapter in the treatment of Duchenne Muscular Dystrophy (DMD) with the introduction of ELEVIDYS (delandistrogene moxeparvovec-rokl), the first gene therapy approved for this devastating disorder. With the U.S. Food and Drug Administration (FDA) granting accelerated approval in June 2023, ELEVIDYS offers hope by addressing the root cause of DMD....0 Comments 0 Shares 239 Views 0 Reviews
-
Breaking Barriers: Innovative Approaches to Treat Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration, primarily affecting boys. While a definitive cure remains elusive, groundbreaking innovations in research and treatment are breaking barriers and providing new hope for patients and their families. This article highlights some of the most promising approaches currently being...0 Comments 0 Shares 245 Views 0 Reviews
-
Pricing and Reimbursement: Gene Therapy's Impact on Healthcare EconomicsGene therapy has emerged as a revolutionary approach to treating genetic disorders, offering potential cures where traditional therapies may only provide symptomatic relief. However, the high costs associated with these therapies have sparked significant debate regarding their pricing and reimbursement strategies. This article examines the economic implications of gene therapy, exploring the...0 Comments 0 Shares 226 Views 0 Reviews
-
Targeting Neuromuscular Diseases with ASOs and siRNA TherapiesNeuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS), involve progressive muscle degeneration and neurological impairments, posing immense challenges for patients and caregivers. However, antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) therapies offer promising solutions by targeting...0 Comments 0 Shares 231 Views 0 Reviews
-
The Future of Duchenne Muscular Dystrophy Treatment: Hope and InnovationDuchenne Muscular Dystrophy (DMD) is a severe genetic disorder caused by mutations in the dystrophin gene, resulting in progressive muscle degeneration. Typically diagnosed in early childhood, the condition leads to the loss of ambulation by adolescence and, without intervention, premature death due to respiratory or cardiac complications. However, recent breakthroughs in medical research and...0 Comments 0 Shares 234 Views 0 Reviews
-
The Long Road to a Cure: Current Progress Against DMDDuchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys. Caused by mutations in the dystrophin gene, DMD leads to the absence of dystrophin, a vital protein for muscle health. Historically, DMD has posed significant challenges for both patients and researchers, with limited treatment options focused...0 Comments 0 Shares 270 Views 0 Reviews